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Abstract The European Society of Hypertension (ESH)/
European Society of Cardiology (ESC) 2013 guidelines for
the management of arterial hypertension included simpli-
fied blood pressure (BP) targets across patient groups, more
balanced discussion on monotherapy vs. combination
therapy, as well as reconfirmation of the importance of out-
of-office BP measurements. In light of these updates, we
wished to review some issues raised and take a fresh look
at the role of calcium channel blocker (CCB) therapy; an
established antihypertensive class that appears to be a
favorable choice in many patients. Relaxed BP targets for
high-risk hypertensive patients in the 2013 ESH/ESC
guidelines were driven by a lack of commanding evidence
for an aggressive approach. However, substantial evidence
demonstrates cardiovascular benefits from more intensive
BP lowering across patient groups. Individualized treat-
ment of high-risk patients may be prudent until more solid
evidence is available. Individual patient profiles and pref-
erences and evidence for preferential therapy benefits
should be considered when deciding upon the optimal
antihypertensive regimen. CCBs appear to be a positive
choice for monotherapy, and in combination with other
agent classes, and may provide specific benefits beyond BP
lowering. Ambulatory and home BP monitoring have an
increasing role in defining the diagnosis and prognosis of
hypertension (especially non-sustained); however, their
value for comprehensive diagnosis and appropriate treat-
ment selection should be more widely acknowledged. In
conclusion, further evidence may be required on BP targets
in high-risk patients, and optimal treatment selection based
upon individual patient profiles and comprehensive diag-
nosis using out-of-office BP measurements may improve
patient management.
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Key Points
While a lack of compelling evidence for aggressive
blood pressure (BP) targets in high-risk patients with
hypertension has driven more relaxed target
recommendations in the European Society of
Hypertension/European Society of Cardiology 2013
guidelines for the management of arterial
hypertension, substantial evidence exists that further
cardiovascular (CV) benefits are available from more
intensive BP lowering. Until more solid evidence is
available, individualized treatment of high-risk
patients may be prudent
Selection of the optimal therapy regimen should be
based on a patient’s individual demographics, BP,
CV risk, co-morbidities, and preference, as well as
evidence for preferential beyond-BP-lowering
benefits of different antihypertensive agents.
Calcium channel blockers are a favorable choice for
monotherapy and in combination with other agent
classes in many patients, and may provide benefits
over other classes for certain CV outcomes
Out-of-office BP measurements provide more
comprehensive information to inform accurate
diagnoses of hypertensive conditions, and are more
prognostic of patient outcome than office
measurements. Ambulatory and home BP
monitoring are likely to play an increasing role in
hypertension management in the future, although
their value for patient evaluation and appropriate
treatment selection should be more widely
acknowledged
1 Introduction
The European Society of Hypertension (ESH) and the
European Society of Cardiology (ESC) guidelines for the
management of arterial hypertension were updated in 2013,
implementing a number of changes since the previous 2007
version [1, 2]. A key amendment for 2013 was the rec-
ommendation for more simplified blood pressure (BP)
targets across groups of patients with hypertension, with all
subjects to be treated to systolic BP (SBP) of\140 mmHg
(apart from elderly patients) and to diastolic BP (DBP) of
\90 mmHg (apart from those with diabetes mellitus) [2].
Further updates in the ESH/ESC guidelines include: more
specific lifestyle recommendations, such as limiting salt
intake to 5–6 g/day and lowering body mass index to
25 kg/m2; more balanced discussion on the advantages and
disadvantages of initiating monotherapy versus combina-
tion therapy; recommendation against dual renin-angio-
tensin system (RAS) blockade (owing to concerns about
renal damage and increased incidence of stroke); recon-
firmation of the importance of ambulatory BP monitoring
(ABPM) and strengthened endorsement of the prognostic
value of home BP monitoring (HBPM) for the diagnosis of
isolated office (‘white coat’) and isolated ambulatory
(‘masked’) hypertension [2].
With regard to the choice of antihypertensive agent, the
2013 ESH/ESC guidelines reconfirm that a diuretic, b-
blocker, calcium channel blocker (CCB), angiotensin II
receptor blocker (ARB), and angiotensin-converting
enzyme (ACE) inhibitor are all suitable for use as mono-
therapy, and in some combinations with each other [2]. Of
these agents, b-blockers appear to be losing favor as rec-
ommended initial monotherapy in other recent guidelines
[3, 4], and the combination of an ARB and an ACE
inhibitor is no longer endorsed [2–4]. Dihydropyridine
CCBs have no compelling contraindications for use and are
a preferred drug in many combination strategies [2],
making them a favorable choice for many hypertensive
patients. Indeed, CCBs have been cleared of the suspicion
of increasing the incidence of coronary events [2, 5]; and
these agents may even be slightly more effective than other
agents in preventing stroke [6–8]. In the light of the ESH/
ESC guidelines update, we wished to take a fresh look at
this established class of antihypertensive agent.
The aim of this article is to review some key issues
raised in the updated 2013 ESH/ESC guidelines, with a
particular focus on the role of CCB therapy.
2 Simplified BP Targets vs. the ‘Lower the Better’
The achieved level of SBP and DBP control is directly
associated with the risk of cardiovascular (CV) disease
(CVD) and stroke, across patient ages and ethnicities [9,
10]. Reducing the incidence of mortality and morbidity
associated with CVD is linked to substantial socioeco-
nomic and healthcare cost savings [11]. Therefore, should
BP targets be more aggressive than suggested in the latest
2013 ESH/ESC guidelines?
The 2013 ESH/ESC recommendation for a BP target of
\140/90 mmHg for most patients is based on a review of
randomized controlled trial (RCT) data [12] that suggested
a lack of evidence for a more aggressive, and previously
recommended, BP target of \130/80 mmHg in patients
with high CV risk [2]. However, the authors of the review
state that despite scant evidence for lowering SBP below
130 mmHg in patients with diabetes or high/very high CV
risk, a more aggressive approach may be prudent because
antihypertensive therapy to lower SBP to \130 mmHg
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appears well tolerated; they suggest more solid trial evi-
dence should be gained [12].
Despite many major trials not achieving BP targets of
\140/90 mmHg, there is a wealth of evidence to indicate a
relationship between lower BP and reduced CV outcomes,
suggesting further benefits are available from greater BP
reductions. Certainly, in low-to-moderate risk patients with
uncomplicated hypertension, trial evidence supports that a
reduction in SBP to \140 vs. [140 mmHg is associated
with reduced adverse CV outcomes [13–15]. Other sup-
portive evidence for intensive BP lowering in a range of
patients is available, showing a lower risk of major CV
events, especially stroke [16, 17] (Table 1). Law et al.
performed a meta-analysis of data from randomized trials
of BP-lowering therapy involving almost half a million
patients (with and without CVD), and observed substantial
reductions in heart disease and stroke for a 10-mmHg
reduction in SBP or a 5-mmHg reduction in DBP, down to
110/70 mmHg [6]. A further meta-analysis of 32 random-
ized trials showed that reduction of SBP to 126 vs.
131 mmHg had the same proportional CV benefits as a
reduction to 140 vs. 145 mmHg [18]. The Heart Outcomes
Prevention Evaluation (HOPE) study demonstrated signif-
icant reductions in the risk of a composite outcome of CV
mortality, myocardial infarction (MI), and stroke following
antihypertensive treatment down to a SBP of 134 mmHg
[19]. Additionally, the Perindopril pROtection aGainst
REcurrent Stroke Study (PROGRESS) trial (in patients
with a history of stroke) revealed that the lowest follow-up
BP levels (median 112/72 mmHg) were associated with the
lowest risk of stroke recurrence, with progressively
increased risk at higher BP levels [20]. The Hypertension
Optimal Treatment (HOT) study revealed the benefits
of intensive lowering of DBP, with a mean DBP of
82.6 mmHg being associated with the lowest incidence
of major CV events and 86.5 mmHg with the lowest risk of
CV mortality [21]. In patients with diabetes, a DBP target
of B80 mmHg was associated with a 51 % reduction in
major CV events compared with a DBP target of
B90 mmHg (p = 0.005) [21]. Conversely, in the Action to
Control Cardiovascular Risk in Diabetes (ACCORD)
study, the authors concluded that intensive BP lowering (to
SBP \120 mmHg) in patients with diabetes failed to
reduce the risk of a composite outcome of fatal and non-
fatal CV events, compared with standard BP reduction (to
SBP \140 mmHg) [22]. However, ACCORD was under-
powered, because the event rate in the standard treatment
arm was around half of that expected; this was reflected in
a wide confidence interval for the primary outcome hazard
ratio (HR) estimate that pointed to a potential 27 % benefit
in favor of intensive treatment (event rate was 2.09 %/year
for standard therapy and 1.87 %/year in the intensive arm).
Furthermore, ACCORD demonstrated significant
improvements in the pre-specified secondary endpoint of
rate of stroke (total and non-fatal) with intensive treatment
(for any stroke: standard therapy, 0.53 %/year; intensive
therapy, 0.32 %/year; p = 0.01) and HR curves for the
primary outcome, stroke, and MI showed separation at
5–8 years, suggesting longer-term CV benefits of tight BP
control. Nonetheless, it should be noted that patients in the
intensive treatment arm of ACCORD demonstrated more
serious treatment-related adverse events (AEs) (including
hypotension, arrhythmia, and hyperkalemia) and reduced
renal function (estimated glomerular filtration rate) [22]. A
meta-analysis of 15 trials of intensive BP lowering dem-
onstrated risk reductions of 11–13 % for major CV events,
MI, and end-stage kidney disease and of 24 % for stroke,
but with no clear effect on mortality [16] (Fig. 1). Intensive
BP reduction did not increase the rate of drug discontinu-
ation or the incidence of serious AEs, apart from hypo-
tension, which occurred infrequently (0.4 %/100 person-
years) [16].
2.1 Would High-Risk Patients Benefit from More
Intensive Treatment?
While \140/90 mmHg appears to be an agreed target for
low-risk hypertensive patients, there is still a lack of con-
sensus among different international guidelines on BP
targets for high-risk patients (Table 2, [2–4, 23–25]). The
recommendation for less aggressive BP targets in high-risk
individuals appears to be a common feature of the more
recent guideline updates [2–4]. Nevertheless, the Canadian
2013 recommendations retained a target BP of \130/
80 mmHg for patients with diabetes [23].
For patients with diabetes, the only trials to achieve a
SBP reduction to \130 mmHg were the normotensive
subgroup of the Appropriate Blood Pressure Control in
Diabetes (ABCD) trial and the ACCORD trial [22, 26].
Both of these trials failed to show the benefit of intensive
BP lowering on their primary outcome (change in creati-
nine clearance and fatal and non-fatal CV events, respec-
tively); however, the positive outcomes from ACCORD are
described above, and ABCD demonstrated that intensive
BP lowering (mean BP of 128/75 vs. 137/81 mmHg) sig-
nificantly slowed the progression of diabetic nephropathy
and retinopathy and reduced the incidence of stroke (all
pre-specified secondary endpoints) [26]. Interestingly, both
of these trials included patients with a baseline BP \140/
85 mmHg, supporting the benefits of BP lowering in
patients with a starting BP lower than the current ESH/ESC
target (\140/90 mmHg). A DBP target of 80–85 mmHg is
supported by the results of the HOT study [21] and the
United Kingdom Prospective Diabetes Study (UKPDS)
[27], and there is evidence for the benefits of lowering SBP
to 130 mmHg, but not lower [22, 28, 29]. Nonetheless,
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more intensive BP lowering (to SBP \130 mmHg) may
reduce organ damage, providing renal and cerebrovascular
protection [30]. The benefits of aggressive BP lowering for
renal protection are particularly striking for patients with
diabetes who have nephropathy; indeed, the Action in
Diabetes and Vascular disease: preterAx and diamicroN
MR Controlled Evaluation (ADVANCE) study verified
that renal events were less frequent in treated patients
(mean SBP 134.7 mmHg at follow-up) compared with
those given placebo (mean 140.3 mmHg), with an associ-
ated antiproteinuric effect and a reduction in the incidence
of new-onset micro- or macro-albuminuria [31]. Patients
with diabetes frequently have a number of co-morbidities,
meaning that an individualized approach to treatment may
be warranted. Hypertensive patients who have experienced
previous CV events have also demonstrated inconsistent
outcomes following intensive antihypertensive treatment
(to SBP \130 mmHg), depending upon the agent used
[32–36]. Furthermore, the optimal BP target for protective
effects on the kidney, brain, and heart may be divergent
[30]. These data support a ‘common sense’ approach in
high-risk individuals, individually tailoring antihyperten-
sive treatment and favoring those agents with proven CV
benefits; however, in clinical practice, the most suitable
drug combinations for any given patient are frequently not
being prescribed.
A number of RCTs involving elderly patients have
shown a reduction in CV events through BP lowering, but
the mean SBP achieved has not reached\140 mmHg [12].
Two recent trials of intensive vs. less intensive treatment
failed to show a benefit of SBP reduction below
140 mmHg [37, 38], while the Felodipine EVEnt Reduc-
tion (FEVER) study sub-analysis showed a reduction in
stroke in 3,179 elderly patients by lowering SBP to just
below 140 mmHg (vs. 145 mmHg) [39]. The Cardio-Sis
trial involving 1,111 elderly patients (mean age: 67 years)
demonstrated that tight BP control (to a mean BP of 132.0/
77.3 mmHg at 2 years) significantly reduced the incidence
of left ventricular hypertrophy and a composite of fatal and
non-fatal CV outcomes compared with usual care (which
reduced mean BP to 135.6/78.9 mmHg at 2 years) [40].
This benefit of intensive treatment was not associated with
an increase in AEs in these patients [40].
Therefore, despite a lack of RCT evidence for aggres-
sive BP targets in high-risk hypertensive patients, which
has driven the relaxed BP targets in the 2013 ESH/ESC
guidelines, a number of studies have shown the benefits of
more intensive BP lowering on various CV outcomes
across patient groups. A ‘ceiling effect’ for treatment
benefits has been described for high-risk patients, sug-
gesting that early therapy to address CV risk before it
reaches a high level may increase the benefit of interven-
tion [41]. While we wait for more comprehensive trial
evidence on BP targets in high-risk patients with hyper-
tension, a move toward more ‘personalized medicine’ may
be prudent for antihypertensive treatment, selecting BP
targets and antihypertensive agents on a per-patient basis
according to the patient clinical profile and the proven CV
benefits of each agent.
3 Monotherapy vs. Combination Therapy
The previous 2007 ESH/ESC guidelines stressed that most
patients would require more than one antihypertensive drug
to achieve their BP target. Conversely, the updated 2013
guidelines present a more balanced discussion of the
advantages and disadvantages of initiating hypertensive
patients on monotherapy vs. combination therapy. Initiat-
ing monotherapy allows clear determination of the drug’s
efficacy and tolerability, while one of the agents may be
ineffective with combination therapy. Monotherapy has a
clear place in the treatment algorithm, especially for grade
1 or mild hypertension [42]. However, when monotherapy
is insufficient or poorly tolerated, finding an alternative
monotherapy that is more effective and/or better tolerated
can be difficult and may discourage adherence. Escalating
the dosage of a prescribed monotherapy may be less
effective for BP reduction than combining agents from
different antihypertensive classes [43]. Combination ther-
apy allows a more prompt BP response vs. up titration of
monotherapy, has a greater probability of achieving target
BP in patients with a higher BP, and may encourage patient
adherence [2]. Compared with monotherapy, combining
antihypertensive drugs also lowers the incidence of major
CV events (stroke and ischemic heart disease) [6] and
initiating low-dose combination therapy may have greater
CV benefits than starting on monotherapy [44]. Addition-
ally, combination of certain classes of antihypertensive
agents has a fully additive effect, allowing earlier, larger,
and more sustained reductions in BP than up titration of
monotherapy and a sequential add-on regimen [44].
The 2013 ESH/ESC guidelines reconfirm the impor-
tance of initiating combination therapy in high-risk patients
and those with markedly high baseline BP [2], with initial
combination therapy generally recommended for patients
with SBP/DBP [15–20/[10 mmHg above the target [44].
3.1 Choice of Antihypertensive Agent
All classes of antihypertensive agent recommended for
monotherapy by the different international societies are
shown in Table 3 [2–4, 23–25, 45]. Overall, the five main
classes of antihypertensive agents (ACE inhibitors, ARBs,
b-blockers, CCBs, and thiazide diuretics) have comparable
clinical efficacy as monotherapy [6, 7, 9]. However,
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b-blockers are losing favor as recommended initial therapy
for most patients because of questions about their efficacy
in preventing stroke and other CV events, and their adverse
effects on glucose metabolism [3, 4]. In contrast, CCBs
have been cleared of the suspicion of increasing the inci-
dence of coronary events [2, 5] and these agents have been
reported to exhibit the lowest inter-individual variation in
SBP vs. other antihypertensive classes, which may be
linked to a reduced risk of stroke [6–8, 46]. However, these
data require confirmation in future trials.
Optimal choice of initial antihypertensive treatment can
establish early benefits of BP control and encourage
adherence. Consideration should be given to the potential
for up titration of monotherapy and later combination
therapy; choosing an efficacious monotherapy that can be
continued as part of a preferred combination regimen may
be beneficial. For example, the Valsartan Antihypertensive
Long-term Use Evaluation (VALUE) study demonstrated
that both CCB (amlodipine)-based and ARB (valsartan)-
based regimens, including stepped up titration of mono-
therapy (5–10 mg/day amlodipine; 80–160 mg/day val-
sartan) followed by combination with a thiazide diuretic,
were similar with regard to the primary outcome of com-
posite cardiac mortality and morbidity. The CCB-based
regimen gave more pronounced BP reduction, especially in
the early stages of treatment (SBP/DBP in amlodipine
group was 4.0/2.1 mmHg lower than in the valsartan group
at 1 month, and 2.1/1.6 mmHg lower at 6 months), and
was associated with a lower incidence of MI and stroke
over the course of the study (mean follow-up 4.2 years)
(Fig. 2) [47]. The stepped up titration of monotherapy in
VALUE may not have been equipotent with regard to the
approved maximal dosing of each agent; however, the
results emphasize the importance of prompt BP control in
high-risk patients with hypertension.
Some agents may have benefits over others in subgroups
of patients [2]; for example, in the Avoiding Cardiovas-
cular events through COMbination therapy in Patients
LIving with Systolic Hypertension (ACCOMPLISH) trial,
combination of an ACE inhibitor with a CCB provided a
20 % relative risk reduction over an ACE inhibitor-diuretic
combination for the primary outcome of composite fatal
and non-fatal CV events in elderly patients with hyper-
tension (age C65 years) [48]. In patients with existing
angina or atrial fibrillation, CCB or b-blocker therapy may
offer additional benefits above BP lowering (a heart-rate-
lowering CCB such as verapamil or diltiazem for rapid
atrial fibrillation); for patients with MI or heart failure, a b-
blocker, ACE inhibitor, or ARB may be preferred; and for
those with peripheral artery disease, an ACE inhibitor or
CCB is recommended [2]. Dihydropyridine CCBs are the
only class of antihypertensive agent with no compelling
contraindications, although they may not be preferred in
patients with peripheral edema or heart conditions (rapid
heart rate, low ejection fraction) [2]. Other classes of
antihypertensive have compelling contraindications when
conditions such as asthma (unselective b-blockers), preg-
nancy, hyperkalemia, or bilateral renal artery stenosis
(ACE inhibitor/ARB) are present [2]. Prescribers should
also consider potential AE profiles when considering
antihypertensive treatment, as these can be strong deter-
rents to patient adherence [49].
CCBs may also be a preferred drug class in many
antihypertensive combination strategies (with ACE inhib-
itors, ARBs, and diuretics) [2]. Combination of nifedipine
GITS (gastrointestinal therapeutic system) with either lo-
sartan or lisinopril has demonstrated greater BP lowering
than with either agent alone [50, 51]; in the mulTicenter
study evALuating the Efficacy of Nifedipine GITS-
b
Table 2 Recommended hypertension treatment targets (SBP/DBP) according to global guideline committees
Guideline (mmHg)
Europe [2] Canada [23] UK [25] International [4] USA [3] China [24]
Diabetes mellitus \140/\85 \130/\80 – \140/\90 \140/\90 \130/\80
Elderly (age C65 years) 140–150/\90a \140/\90 \140/\90 \140/\90 \150/\90a \150/\90a
Very elderly (age C80 years) 140–150/\90 \150/\90 \150/\90 \150/\90 – –
CKD \140/\90 \140/\90 – \140/\90 \140/\90 \130/\80
All others \140/\90 \140/\90 \140/\90 \140/\90 \140/\90 \140/\90
– not specified individually, CKD chronic kidney disease, DBP diastolic blood pressure, SBP systolic blood pressure
a \140/90 mmHg, if tolerable
Fig. 1 Effect of intensive BP lowering on risk of CV outcomes:
a major CV events, b MI, c stroke, and d CV mortality. AASK African
American Study of Kidney Disease and Hypertension, ABCD
Appropriate Blood pressure Control in Diabetes, ACCORD Action
to Control Cardiovascular Risk in Diabetes, BP blood pressure, CI
confidence interval, CV cardiovascular, HOT Hypertension Optimal
Treatment, JATOS Japanese trial to assess optimal systolic blood
pressure in elderly hypertensive patients, MI myocardial infarction,
REIN-2 Ramipril Efficacy in Nephropathy 2, UKPDS-HDS United
Kingdom Prospective Diabetes Study-Hypertension in Diabetes
Study. Reprinted from [16]
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Telmisartan combination in BP control and beyond
(TALENT), initial combination therapy provided greater
and earlier (from 2 weeks) 24-h BP control vs.
monotherapy [52]. The Avoiding Cardiovascular events
through Combination therapy in Patients Living with
Systolic Hypertension (ACCOMPLISH) study was the only
Table 3 Recommendations regarding monotherapy and combination hypertension treatment according to global guideline committees
ESH/ESC (Europe) [2] Diuretics, CCBs, ACE inhibitors, ARBs, and b-blockers are suitable for the initiation and maintenance
of treatment, alone or in combination
Combination therapy should be considered in patients at high risk or with markedly high BP. CCB-ACE
inhibitor, CCB-ARB, and CCB-thiazide diuretic are preferred combinations
NICE (UK) [25] CCBs are recommended as first line in patients aged C55 years and in Blacks of African or Caribbean
origin of any age (unless compelling indications against). Other patients aged \55 years may be
offered an ACE inhibitor or a low-cost ARB
The combination of a CCB-ACE inhibitor or CCB-ARB are recommended as second-line treatment
options
ISH-ASH (international) [4] An ACE inhibitor or ARB should be initiated as monotherapy in non-Black patients aged\60 years and
a CCB or thiazide diuretic in those aged [60 years (CCB or thiazide diuretic recommended for all
Black patients)
Dose adjustment or a combination with another class of agent should be considered every 2–3 weeks if
response is not seen. Combination therapy (CCB or thiazide diuretic plus ACE inhibitor or ARB)
should be considered first line in patients with BP C20/10 mmHg above the target
International Society on Hypertension
in Blacks [45]
In the absence of compelling indications, when BP is near goal levels, monotherapy with a diuretic or a
CCB is preferred because of a greater likelihood of attaining goal BP with either of these agents as
monotherapy in Blacks. Combination therapy should be initiated when SBP is [15 mmHg and/or
DBP is [10 mmHg above goal levels. CCBs or diuretics in combination with each other or with an
ACE inhibitor or ARB are recommended
Canadian Hypertension Education
Program [23]
Thiazide diuretics, b-blockers (in patients aged \60 years), ACE inhibitors (in non-Black patients),
long-acting CCBs or ARBs are recommended as initial monotherapy. Combination of two first-line
drugs may be considered as initial therapy if SBP is[20 mmHg or DBP[10 mmHg above the target.
Two-drug combinations of b-blockers, ACE inhibitors, and ARBs are not recommended
Joint National Committee (USA) [3] Thiazide-type diuretics, CCBs, ACE inhibitors, or ARBs are recommended as initial treatment in non-
Black patients with hypertension and thiazide-type diuretics or CCBs for the general Black
population. If goal BP is not reached within 1 month, up titration or combination with another class of
agent should be considered. ACE inhibitors and ARBs are recommended to be included in
antihypertensive therapy in patients with CKD, to improve kidney outcomes
Chinese Hypertension League [24] Thiazide diuretics, CCBs, ACE inhibitors, ARBs, and b-blockers can be used for initial or maintenance
therapy, alone or in combination
ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, BP blood pressure, CCB calcium channel blocker, CKD chronic
kidney disease, DBP diastolic blood pressure, ESC European Society of Cardiology, ESH European Society of Hypertension, ISH-ASH Inter-
national Society of Hypertension/American Society of Hypertension, NICE National Institute for Health and Clinical Excellence, SBP systolic
blood pressure
Fig. 2 OR for major CV events for antihypertensive treatment with
ARB-based therapy (valsartan) vs. CCB-based therapy (amlodipine).
ARB angiotensin II receptor blocker, CCB calcium channel blocker,
CV cardiovascular, OR odds ratio, SBP systolic blood pressure D SBP
represents the difference in SBP between the treatment groups
(amlodipine-valsartan). Primary endpoint consisted of a composite of
cardiac morbidity and mortality. Reprinted from [47], Copyright
(2013), with permission from Elsevier
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large trial to directly compare RAS blockade in combina-
tion with either a CCB or a diuretic, and demonstrated the
benefit of an amlodipine-benazepril combination over a
hydrochlorothiazide (HCTZ)-benazepril combination for
reducing CV events in high-risk patients with hypertension
[48]. However, the combination of RAS blockade with a
diuretic has shown beneficial outcomes in particular sub-
groups of patients, such as those with congestive heart
failure [53], and an ACE inhibitor/diuretic combination
appears to demonstrate a particular additive efficacy in
Black patients [54]. In the Losartan Intervention For
Endpoint reduction in hypertension (LIFE) study, an ARB/
diuretic combination (losartan/HCTZ) showed significantly
better reductions in CV morbidity and mortality for similar
BP reduction, largely attributable to superior stroke pre-
vention [55]. The Anglo-Scandinavian Cardiac Outcomes
Trial (ASCOT) showed lower visit-to-visit BP variability
with a CCB-ACE inhibitor combination (amlodipine
based) vs. a b-blocker-diuretic combination (atenolol
based), and the CCB-ACE inhibitor combination was
associated with a 34 % reduction in new-onset diabetes
[56]. Dual RAS blockade is no longer recommended owing
to concerns regarding renal damage and an increased
incidence of stroke [57, 58].
International guidelines vary in their recommendations
toward initiating monotherapy vs. combination therapy
(Table 3). However, these guidelines provide some con-
sistent recommendations on the choice of agent; for
example, CCB use in both monotherapy and combination
therapy is highlighted favorably in the European (ESH/
ESC), the United Kingdom (National Institute for Health
and Clinical Excellence), American (Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure), and Canadian (Canadian
Hypertension Education Program) guidelines, as well as
the International Society of Hypertension/American Soci-
ety of Hypertension and the Chinese Hypertension League
guidelines [2–4, 23–25]. The use of ACE inhibitors and
ARBs is also recommended.
Therefore, each patient’s individual demographics, BP
level, CV risk, co-morbidities, and preference (including
any previously reported side effects), as well as the evi-
dence for preferential antihypertensive agent benefits,
should be considered when deciding upon the optimal
regimen and type of antihypertensive treatment. CCBs
appear to be a favorable choice of antihypertensive agent
for monotherapy and in combination with other agent
classes, and may provide benefits over other classes for
certain patient groups and CV outcomes. Further research
is needed into specific beyond BP-lowering class effects,
but CCBs are an established group of antihypertensive
agents that looks to play a sustained role in future hyper-
tension treatment strategies.
4 Diagnosis and Monitoring of Hypertension
The importance of ABPM and HBPM for the diagnosis and
monitoring of hypertension has been known for some time,
and newer guidelines, including the 2013 ESH/ESC rec-
ommendations, are recognizing this and providing diag-
nostic thresholds [2, 25]. An official position paper on
ABPM has also recently been published [59]. Office BP is
usually higher than ABPM and HBPM; a large study of
ABPM vs. clinic BP measurements found that the latter
were on average 6/3 mmHg higher than the daytime
ambulatory BP and 10/5 mmHg higher than 24-h ABPM
values [60]. These data have important consequences for
accurate diagnosis and selection of optimal treatment
strategies. This difference in BP according to the mea-
surement technique used is reflected in the current ESH/
ESC recommended definitions of hypertension using each
method (Table 4).
The most commonly used ABPM parameters are mean
daytime, mean night-time, mean 24-h BP, and BP load. BP
load is defined as the percentage of readings in a given time
period (day, night, 24 h) that exceed a pre-defined thresh-
old BP (typically the ‘normal’ BP for that period). How-
ever, differences in BP load can be largely explained by
differences in BP variability and no information on the
extent to which the threshold has been exceeded is pro-
vided, which is of prognostic importance. The consistency
of antihypertensive treatment over a 24-h period is reflec-
ted by the trough:peak ratio and smoothness index, derived
from 24-h ABPM data. Trough:peak ratios are highly
variable within any individual and are thus not a reliable
clinical measure. Conversely, the smoothness index reflects
the size of BP reduction with treatment and homogeneity
throughout the 24-h period (higher values signifying anti-
hypertensive treatments with a large and consistent effect).
A higher smoothness index (lower BP variability) is
associated with improved CV outcomes and reduced organ
damage [61]. Classification of daytime and night-time
periods may be best done using information from patient
diaries on their sleep patterns; however, fixed time periods
Table 4 ESH/ESC definitions of hypertension using office and out-
of-office BP measurements
Office BP measurement SBP C140 mmHg and/or DBP C90 mmHg
Ambulatory BP measurements
Daytime (awake) SBP C135 mmHg and/or DBP C85 mmHg
Night-time (asleep) SBP C120 mmHg and/or DBP C70 mmHg
24-h SBP C130 mmHg and/or DBP C80 mmHg
Home BP measurement SBP C135 mmHg and/or DBP C85 mmHg
BP blood pressure, DBP diastolic blood pressure, ESC European
Society of Cardiology, ESH European Society of Hypertension, SBP
systolic blood pressure
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representing day (09:00–21:00) and night (01:00–06:00)
are common, eliminating much of the inter- and intra-
patient variability, but sacrificing early-phase night sleep
BP dipping and early morning surge information, which
have significance for CV outcomes. Different BP sampling
intervals can be employed; however, it is recommended not
to exceed 30 min between readings, to avoid incorrect
estimation of mean values [59]. It is recommended to
repeat ABPM measurement if \70 % of the expected
measurements within 24 h are recorded, including 20 valid
awake and seven valid sleep measurements [59]. ABPM
readings are usually performed on the non-dominant arm
(to reduce disruption to everyday activities), but there is
currently a lack of consensus regarding the most suitable
arm position for the patient to adopt during measurements,
with implications for data accuracy [62].
ABPM and HBPM may have greater prognostic value
for risk of CV events than office measurements [2, 63, 64]
and ABPM is associated with a doubling of BP control
rates vs. office measurements [65]. Central BP measure-
ment has also been noted as an independent predictor of
CV events in various populations; however, its relative
value vs. brachial measurements is still under debate [2]
and the benefit of achieving central BP reduction through
antihypertensive treatment for patient outcomes has been
investigated [Nifedipine GITS’s Effect on Central Pressure
Assessed by Applanation Tonometry (FOCUS) study,
NCT01071122].
Therapeutic decisions based on ABPM are superior to
those based on office measurements [66]; for instance, the
Valsartan in Systolic Hypertension (Val-Syst) trial dem-
onstrated that the treatment-induced reduction in clinic SBP
was considerably greater than the mean 24-h BP reduction,
measured by ABPM (31.9 vs. 13.4 mmHg, respectively),
which was attributable to a white coat effect [67]. Fur-
thermore, in patients with white coat hypertension, no
change was seen in 24-h BP or that in the hour following
treatment, whereas a large decrease in SBP was seen [67].
Had ABPM not been used, this apparent BP-lowering effect
would have been wrongly attributed to treatment. Indeed,
ABPM has been shown to be the most cost-effective strat-
egy for diagnosing hypertension in patients of all ages, with
the additional costs of initial diagnosis offset by savings
from targeted treatment [68, 69].
HBPM offers more extensive data than office BP mea-
surement can provide, is less expensive, is widely available
and convenient, and has been shown to improve patient
compliance with treatment and BP control [68]. In a study
of 80 patients, HBPM was demonstrated to lead to fewer
erroneous diagnoses compared with office BP measure-
ment (3.8 % vs. 15 %, respectively), and was more effec-
tive for monitoring the effect of therapy in mild or
moderate hypertension [70]. BP variability measured by
HBPM was also not significantly different to that derived
from ABPM [70]. However, unlike ABPM, HBPM does
not include BP during sleep or work and cannot capture
short-term variability; therefore, HBPM should be consid-
ered complementary to ABPM [71]. Once concordance
between HBPM and ABPM can be established, HBPM
may be appropriate for long-term monitoring [68]. A new
study [Targets and self-management for the control of BP
in stroke and at-risk groups (TAMSIN-SR)] will assess the
value of HBPM for self-management of hypertension in
high-risk patients [72].
ABPM and HBPM are vital for the diagnosis of patients
with non-sustained hypertension, who may still be at risk of
adverse CV events [73]. White coat hypertension is asso-
ciated with a lower risk of organ damage and CV events
than sustained hypertension, and patients with raised BP on
ABPM or HBPM show increased risk of CV and all-cause
mortality [73]. Moreover, patients with white coat hyper-
tension may respond differently to antihypertensive agents,
and develop more AEs, compared with patients who have
sustained hypertension [66]. Masked hypertension is pre-
valent in those with chronic kidney disease, diabetes, and
obstructive sleep apnea [74]. These patients may only have
high normal office BP, but demonstrate a greater risk for
organ damage and CV events than patients with white coat
hypertension [2]. However, many patients with non-sus-
tained (or masked) hypertension remain undiagnosed, pre-
senting a hidden risk for future CV events. Waiting to treat
hypertension increases total risk, and progression to high
risk is often not entirely reversible [41]. Therefore, diag-
nosing and treating non-sustained hypertension is likely to
be beneficial in the longer term. Nonetheless, classification
of patients based solely on differences between in- and out-
of-office BP measurements may be misleading, as it may
not consider the significance of BP during sleep [75].
Many international guidelines are now in agreement that
ABPM should be used for the exclusion or confirmation of
white coat hypertension, with a move towards its use to
diagnose hypotension and resistant hypertension, to moni-
tor therapy efficacy over a 24-h period, as well as for
assessing nocturnal BP dipping (difference between day-
time and night-time BP) [59]. Indeed, there is compelling
evidence that data on nocturnal BP levels may be superior
to office BP measurements in predicting patient outcome
[59], supporting greater use of ABPM generally. White
coat hypertension, nocturnal dipping, nocturnal hyperten-
sion, and increased BP variability are more common in
high-risk patients than in low-risk patients with high BP;
these conditions are best characterized using ABPM,
allowing improved management of patients already at
increased risk of CV events [59].
Overall, the value of ABPM and HBPM for the diag-
nosis and monitoring of hypertension needs to be more
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widely understood and utilized, and clear strategies and BP
targets established for these methods.
5 Conclusions
The 2013 ESH/ESC hypertension management guidelines
recommend a more unified BP target for most patients,
owing to a lack of compelling RCT evidence for the pre-
viously more aggressive BP targets in high-risk patients.
However, substantial evidence suggests that further CV
benefits are available from more intensive BP lowering
and, until more solid RCT data are available, individual-
ized treatment of high-risk patients may be prudent. Indi-
vidual patient demographics, BP level, CV risk, co-
morbidities, and preference should influence the chosen
treatment strategy. An optimal therapy regimen that lowers
BP and CV risk while being tolerable will encourage
patient adherence. CCBs appear to be a favorable choice
for monotherapy and in combination (with other antihy-
pertensive agent classes) in many patients, and may pro-
vide specific beyond-BP-lowering benefits. The importance
of ABPM and HBPM for comprehensive diagnosis of
hypertensive conditions, patient risk stratification, and
appropriate treatment selection should be more widely
acknowledged and utilized. These methods are likely to
play an increasing role in the hypertension field.
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